Area | Drugs n | Market entry probability | Cumulative | ||
Phase II | Phase III | Approved | |||
HIV/AIDS | 108 | 75 | 50 | 36 | 14 |
Dermatology | 122 | 8 | 44 | 29 | 11 |
Haematology | 163 | 60 | 4 | 22 | 9 |
Neurology | 192 | 73 | 47 | 22 | 8 |
Cancer | 68 | 78 | 46 | 20 | 7 |
Cardiovascular | 280 | 69 | 4 | 22 | 6 |
Respiratory | 165 | 68 | 31 | 16 | 3 |
Data are presented as %, unless otherwise stated. Adapted from [7].